1. Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk
Zongru LI ; Ting ZHAO ; Yanrong LIU ; Yazhe WANG ; Lanping XU ; Xiaohui ZHANG ; Yu WANG ; Hao JIANG ; Yuhong CHEN ; Huan CHEN ; Wei HAN ; Chenhua YAN ; Jing WANG ; Jinsong JIA ; Xiaojun HUANG ; Qian JIANG
Chinese Journal of Hematology 2019;40(7):554-560
Objective:
To explore the significance of minimal residual disease (MRD) in predicting prognosis and guiding therapy of adults with Philadelphia-chromosome negative acute lymphoblastic leukemia (Ph- ALL) in high-risk.
Methods:
Data of newly diagnosed adults with Ph- ALL in high-risk who achieved CR were reviewed. Variables associated with outcome were identified by COX regression model and Landmark analysis.
Results:
A total of 177 patients, 99 (56%) cases male with a median age of 40 years (range, 16-65 years) were included in this study. Of them, 95 (54%) patients received allo-HSCT in CR1. Multivariate analyses showed that MRD negativity after the first cycle of consolidation (
2.Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent.
Zongru JIANG ; Li WANG ; Xuesong LIU ; Cheng CHEN ; Beilei WANG ; Wenliang WANG ; Chen HU ; Kailin YU ; Ziping QI ; Qingwang LIU ; Aoli WANG ; Jing LIU ; Guangchen HONG ; Wenchao WANG ; Qingsong LIU
Acta Pharmaceutica Sinica B 2020;10(3):488-497
Angiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment. However, most of currently used VEGFR2 kinase inhibitors are multi-target inhibitors which might result in target-associated side effects and therefore limited clinical toleration. Highly selective VEGFR inhibitors are still highly demanded from both basic research and clinical application point of view. Here we report the discovery and characterization of a novel VEGFR2 inhibitor (CHMFL-VEGFR2-002), which exhibited high selectivity among structurally closed kinases including PDGFRs, FGFRs, CSF1R, etc. CHMFL-VEGFR2-002 displayed potent inhibitory activity against VEGFR2 kinase in the biochemical assay (IC = 66 nmol/L) and VEGFR2 autophosphorylation in cells (ECs ∼100 nmol/L) as well as potent anti-proliferation effect against VEGFR2 transformed BaF3 cells (GI = 150 nmol/L). In addition, CHMFL-VEGFR2-002 also displayed good anti-angiogenesis efficacy and exhibited good PK (pharmacokinetics) profile with bioavailability over 49% and anti-angiogenesis efficacy in both zebrafish and mouse models without apparent toxicity. These results suggest that CHMFL-VEGFR2-002 might be a useful research tool for dissecting new functions of VEGFR2 kinase as well as a potential anti-angiogenetic agent for the cancer therapy.